# Inflammation in osteonecrosis of the femoral head: Evaluation of hematological biomarkers and potential prognostic value

**Authors:** Tran Canh Tung Nguyen, Dao Doan Trinh Phan, Thi Huyen Do, Thanh Nam Luong, Hoang Khang Le

PMC · DOI: 10.1371/journal.pone.0346158 · PLOS One · 2026-03-27

## TL;DR

This study found that inflammation markers like CRP and monocyte levels are higher in people with osteonecrosis of the femoral head, suggesting they could help diagnose and monitor the disease.

## Contribution

The study identifies CRP and monocyte indices as potential low-cost biomarkers for early detection and monitoring of nontraumatic ONFH.

## Key findings

- ONFH patients had significantly higher CRP, monocyte count, and MLR compared to controls.
- CRP and monocyte count showed the highest diagnostic accuracy for ONFH detection.
- CRP levels varied by disease stage, peaking at stage II, while other markers remained stable.

## Abstract

Increasing evidence suggests that inflammation and immune imbalance are associated with osteonecrosis of the femoral head (ONFH). This study aimed to investigate peripheral inflammatory biomarkers in patients with nontraumatic ONFH and assess their potential prognostic value. A retrospective analysis was conducted on 80 patients with nontraumatic ONFH and 110 control individuals without ONFH. Peripheral blood cell counts, C-reactive protein (CRP), and derived inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were compared between groups and among different disease stages. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis. The results showed that ONFH patients showed significantly higher CRP, monocyte count (cM), monocyte percentage (pM), MLR, and platelet count (PLT). ROC analysis revealed that CRP (AUC = 0.700, sensitivity = 71.3%, specificity = 65.5%) and cM (AUC = 0.690, sensitivity = 82.5%) had the highest diagnostic accuracy. CRP levels differed significantly across disease stages, peaking at stage II (P = 0.0107), while other indices remained stable. These findings support the concept that both systemic and local inflammatory mechanisms contribute to the pathogenesis of ONFH. CRP and monocyte indices may serve as inexpensive, accessible adjuncts for early disease screening and monitoring.

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CSF1R (colony stimulating factor 1 receptor) [NCBI Gene 1436] {aka BANDDOS, C-FMS, CD115, CSF-1R, CSFR, FIM2}, IL34 (interleukin 34) [NCBI Gene 146433] {aka C16orf77, IL-34}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** hypertension (MESH:D006973), immune dysregulation (OMIM:614878), intervertebral disc degeneration (MESH:D055959), liver disease (MESH:D008107), inflammatory rheumatic conditions (MESH:D012213), knee osteoarthritis (MESH:D020370), sclerosis (MESH:D012598), hip joint deformity (MESH:D006617), Takayasu arteritis (MESH:D013625), necrosis (MESH:D009336), edema (MESH:D004487), bone tissue damage (MESH:D018213), necrotic degeneration of (MESH:D009410), Inflammation (MESH:D007249), thrombosis (MESH:D013927), degenerative musculoskeletal disorders (MESH:D009140), ischemic (MESH:D002545), autoimmune conditions (MESH:D001327), coagulation abnormalities (MESH:D001778), femoral head necrosis (MESH:D005271), metabolic disorders (MESH:D008659), chronic (MESH:D002908), malignant tumors (MESH:D009369), tissue injury (MESH:D017695), systemic (MESH:D015619), Osteonecrosis of the femoral head (MESH:D000070603), AS (MESH:D013167), immune (MESH:D007154), hip arthritis (MESH:D001168), avascular necrosis (MESH:D010020), bone marrow (MESH:D001855), ischemia (MESH:D007511), vascular occlusion (MESH:D008641), diabetes mellitus (MESH:D003920), axSpA (MESH:D000089183), osteoarthritis (MESH:D010003), inflammatory and degenerative disorders (MESH:D019636), RA (MESH:D001172), infections (MESH:D007239), Trauma (MESH:D014947), HIV (MESH:D015658), vascular compromise (MESH:D057772), loss of mobility (MESH:D014086)
- **Chemicals:** steroid (MESH:D013256), reactive oxygen species (MESH:D017382), alcohol (MESH:D000438), nitric oxide (MESH:D009569)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028480/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13028480/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028480/full.md

---
Source: https://tomesphere.com/paper/PMC13028480